Who is sponsoring NCT03886922?

NCT03886922 is sponsored by Danish Headache Center.

What drugs are being tested in NCT03886922?

Interventions in NCT03886922: Levcromakalim, Saline.

What condition does NCT03886922 study?

NCT03886922 studies Hemodynamics of Cranial Arteries, Headache, Cerebral Blood Flow.

Is NCT03886922 still recruiting?

NCT03886922 is currently status unknown. Last updated 7 July 2022.

Last reviewed 2022-07-07 · How we verify

NCT03886922

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Hemodynamics Effect of Glibenclamide on Levcromakalim Assessed by High Resolution Magnetic Resonance Angiography (MRA) Technique in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers

Status unknown NA Last updated 7 July 2022

What this trial tests

NA trial testing Levcromakalim in Hemodynamics of Cranial Arteries in 15 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
30 August 2023

30 August 2023

Quick facts

Lead sponsor	Danish Headache Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	15
Start date	1 April 2019
Primary completion	30 August 2023
Estimated completion	30 August 2023
Sites	2 locations across Denmark

Drugs / interventions tested

Levcromakalim — full drug profile →
Saline

Conditions studied

Hemodynamics of Cranial Arteries — all drugs for Hemodynamics of Cranial Arteries →
Headache — all drugs for Headache →
Cerebral Blood Flow — all drugs for Cerebral Blood Flow →

Sponsor

Danish Headache Center — full company profile →

Who can join

Adults 18 to 60, any sex, with Hemodynamics of Cranial Arteries or Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effect of levcromakalim/placebo infusion on cranial arteries after glibenclamide administration.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of K<sub>ATP</sub> channel blocker glibenclamide on levcromakalim-induced headache.
Al-Karagholi MA, Ghanizada H, Kokoti L, Paulsen JS, et al · · 2020 · cited 21× · PMID 32806954 · DOI 10.1177/0333102420949863
Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers.
Al-Karagholi MA, Ghanizada H, Nielsen CAW, Ansari A, et al · · 2021 · cited 19× · PMID 33028147 · DOI 10.1177/0271678x20959294
ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential.
Clement A, Guo S, Jansen-Olesen I, Christensen SL. · · 2022 · cited 18× · PMID 35954249 · DOI 10.3390/cells11152406
Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial.
Kokoti L, Al-Karagholi MA, Waldorff Nielsen CA, Ashina M. · · 2023 · cited 5× · PMID 36763326 · DOI 10.1007/s13311-023-01350-y

Verify or expand the search:

Other trials of Levcromakalim

Trials testing the same drug.

NCT05889442 — Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab · NA · completed
NCT05565001 — The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. · NA · unknown
NCT05243953 — Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache · NA · completed
NCT05211050 — Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine · NA · completed
NCT04905654 — Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura · NA · completed

Other Danish Headache Center trials

Trials by the same sponsor.

NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03886922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
Last refreshed: 7 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03886922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing